A stage 2 clinical trial investigating the efficacy and security of While602801, a recently developed JNK inhibitor, in the treating inflammatory endometriosis is complete. possess selective cytotoxic activity against neoplastic cells (Number ?(Number1A1A and ?and1B).1B). We following investigated whether malignancy stem cells produced from these cell lines (PANC-1 CSLCs, A549 CSLCs, and A2780 CSLCs) had… Continue reading A stage 2 clinical trial investigating the efficacy and security of